Even as he leads a national clinical trial testing
a combination of paclitaxel chemotherapy with an experimental agent known as efatutazone, Dr. Smallridge is working with Dr. Copland and researcher Laura Marlow to find an HDAC inhibitor that might offer additional benefit.
Not exact matches
When 2 years ago Hackett discovered a new way
of using a lipid to link drugs to the soluble protein albumin, and that the
combination showed promise in improving the bioavailability
of the chemotherapy agent
paclitaxel, he and his adviser thought they had an invention that laid the foundation for a company.
A
combination of fostamatinib and
paclitaxel reduced tumor size in six mice by up to 87 percent, compared with no shrinkage in six untreated animals after three weeks.
Based on results
of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the
paclitaxel - fostamatinib
combination therapy in patients with recurrent advanced ovarian cancer.
Based on what is already known about fostamatinib toxicity, Shih says that patients using a
combination of fostamatinib and
paclitaxel may experience side effects that include low white blood cell counts, nausea, vomiting and diarrhea.
The current standard
of care for advanced pancreatic cancer — a
combination of nab -
paclitaxel and gemcitabine — was developed by TGen and the HonorHealth Research Institute, and approved by the U.S. Food and Drug Administration in 2013.
TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in
combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use
of trebananib in front - line treatment adding it to carboplatin /
paclitaxel.
Randomized Phase III Study
of Maintenance Therapy with Bevacizumab, Pemetrexed, or a
Combination of Bevacizumab and Pemetrexed Following Carboplatin,
Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Paclitaxel (Taxol ®) is a widely - used anticancer agent for treatment
of ovarian, breast, lung, head, and neck cancer with two serious side effects: myelosuppression and peripheral sensory neurotoxicity which limits its use in high / cumulative doses or in
combination with other anticancer agents.
In 2013, Abraxane (nanoparticle albumin — bound formulation
of paclitaxel) was approved in
combination with gemcitabine for metastatic pancreatic cancer.